An observational study in Breast Cancer, HER2-negative Breast Cancer and Hormone Receptor Positive Breast Carcinoma, sponsored by Institut fuer Frauengesundheit. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-23.
Sponsored by Institut fuer Frauengesundheit · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.
Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is the only one that started in 2023, is one of 2 observational ones, and was the 7th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:
Institut fuer Frauengesundheit · Sites in Germany
Women only
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+ · Women only
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 183 across the 8 interventional studies, 1,600 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut fuer Frauengesundheit is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
1 of the studies in Breast Neoplasms by Institut fuer Frauengesundheit that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07531693Institut fuer FrauengesundheitPatient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional retrospective cohort study of premenopausal patients with HR+/HER2- breast cancer who are treated in the adjuvant setting with either Tamoxifen, Tamoxifen + Ovarial Function Suppression or Aromatase inhibitor + Ovarial Function Suppression.
The treatment landscape concerning the adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor positive (HRpos) breast cancer is quite heterogeneous and therapy recommendations can vary. Tamoxifen (TAM) is a common treatment option that does not require OFS, but research suggests that adding OFS to tamoxifen may improve outcomes. Aromatase inhibitors (AI) are another option, but they can only be used with OFS for premenopausal patients. Studies have shown that AI + OFS improves disease-free survival compared to TAM + OFS, but it may lead to additional side effects such as osteopenia and bone fractures.
The CLEAR-B study aims to provide a detailed description of the therapy landscape in this therapeutic setting, including recurrence rates and overall survival with AI compared to TAM, as well as a comparison of the chosen therapies within prognostic subgroups.
CLEAR-B is a retrospective cohort study, collecting data of premenopausal patients who were diagnosed with early-stage breast cancer between January 2016 and June 2019 in a certified breast cancer center. These patients had an intermediate or high risk of cancer recurrence, as defined by (neo)adjuvant chemotherapy, and/or pT≥2cm at the timepoint of definitive surgery and/or at least one positive lymph node at the time of definite surgery (pN+).
The primary objective is to compare the invasive disease-free survival (iDFS) of patients who were treated with AI + OFS vs. those who were treated with TAM ± OFS. Additionally, the study will compare distant disease-free survival (DDFS) and overall survival (OS) between the two groups and perform subgroup analyses according to risk stratification (stage II and III). This study will be conducted at around 75 certified breast cancer centers and will enroll up to 3000 patients.
Premenopausal patients with early-stage breast cancer who have been diagnosed from January 2016 to June 2019 with an intermediate or high recurrence risk in a certified breast cancer center (DKG/DGS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Premenopausal defined as all statements must be true
Patients with an intermediate or high-risk early-stage breast cancer defined as: At least one of the following must be fulfilled
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adjuvant treatment with aromatase inhibitor + OFS (ovarian function suppression)
Patients started the adjuvant treatment with Tamoxifen ± OFS
iDFS
The primary study aim is to show that aromatase inhibitor (AI) based treatments (AI arm) are not inferior to treatments based on tamoxifen (tamoxifen arm) in terms of invasive diseasefree survival (iDFS). iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of iDFS
In case non-inferiority is confirmed, the superiority of Cohort AI+OFS over Cohort TAM will be tested with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of DDFS
To analyze the non-inferiority of the Cohort AI+OFS compared with the Cohort TAM with regard to distant disease-free survival (DDFS). DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of OS
To analyze the non-inferiority of the Cohort AI+OFS compared with the Cohort TAM with regard to overall survival (OS). In case non-inferiority is confirmed, the superiority of Cohort AI+OFS over Cohort TAM will be tested with regard to OS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.
Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years
Comparison of iDFS in Cohort TAM
To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of DDFS in Cohort TAM
To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of OS in Cohort TAM
To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.
Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years
Comparison of iDFS (TAM+OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were treated with OFS with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of DDFS (TAM+OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were treated with OFS with regard to DDFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of OS (TAM+OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM who were treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.
Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years
Comparison of iDFS (TAM-OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were not treated with OFS with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of DDFS (TAM-OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were not treated with OFS with regard to DDFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.
Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years
Comparison of OS (TAM-OFS and AI+OFS)
To compare patients of Cohort AI+OFS with patients in Cohort TAM who were not treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.
Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years
Influence of disease stage
To conduct multivariate analyses to estimate the influence of disease stage on prognosis.
Time frame: Baseline until onset of disease progression or death up to 5 years
Risk Factors
To conduct subgroup analyses for the survival outcomes (iDFS, DDFS, OS) according to risk stratification (stage II and stage III)
Time frame: Baseline until onset of disease progression or death up to 5 years
NATALEE Comparison
To compare patients who are matching the inclusion and exclusion criteria of the pivotal study NATALEE and who were treated in Cohort AI+OFS with patients matching the NATALEE population and who were treated in Cohort TAM.
Time frame: Baseline until onset of disease progression or death up to 5 years
Therapy frequencies
To assess the frequency of the different therapies according to risk groups
Time frame: Baseline
Adherence
Number of patients with specified reason for therapy termination (recurrence, side effects, patients' wishes etc.)
Time frame: End of Treatment/ Treatment termination up to 5 years
Started Mar 2023 (actual). Primary completion is estimated for Dec 2023, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut fuer Frauengesundheit